Pyxis Oncology (PYXS) Projected to Post Quarterly Earnings on Tuesday

Pyxis Oncology (NASDAQ:PYXS) will likely be releasing its Q4 2025 results before the market opens on Tuesday, March 17th. Analysts expect Pyxis Oncology to announce earnings of ($0.35) per share for the quarter. Parties may visit the the company’s upcoming Q4 2025 earning results page for the latest details on the call scheduled for Friday, March 20, 2026 at 12:30 PM ET.

Pyxis Oncology Price Performance

Pyxis Oncology stock opened at $1.50 on Tuesday. Pyxis Oncology has a 1-year low of $0.83 and a 1-year high of $5.55. The stock has a market cap of $93.39 million, a PE ratio of -0.94 and a beta of 1.45. The stock’s fifty day moving average is $1.49 and its two-hundred day moving average is $2.50.

Hedge Funds Weigh In On Pyxis Oncology

A number of large investors have recently bought and sold shares of PYXS. Maia Wealth LLC acquired a new stake in shares of Pyxis Oncology in the 4th quarter worth $25,000. Engineers Gate Manager LP acquired a new stake in Pyxis Oncology in the fourth quarter valued at about $26,000. Fox Run Management L.L.C. purchased a new stake in Pyxis Oncology in the 4th quarter valued at approximately $26,000. XTX Topco Ltd acquired a new position in Pyxis Oncology during the 2nd quarter worth approximately $40,000. Finally, LPL Financial LLC raised its stake in shares of Pyxis Oncology by 150.7% during the 4th quarter. LPL Financial LLC now owns 35,102 shares of the company’s stock worth $40,000 after buying an additional 21,100 shares in the last quarter. Hedge funds and other institutional investors own 39.09% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have commented on the stock. Stephens increased their price target on shares of Pyxis Oncology from $5.00 to $8.00 and gave the company an “overweight” rating in a research note on Monday, November 24th. Wall Street Zen upgraded shares of Pyxis Oncology from a “sell” rating to a “hold” rating in a report on Saturday. Royal Bank Of Canada cut their price target on shares of Pyxis Oncology from $8.00 to $5.00 and set an “outperform” rating on the stock in a research note on Thursday, December 18th. HC Wainwright upped their price objective on shares of Pyxis Oncology from $5.00 to $7.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Pyxis Oncology in a research report on Thursday, January 22nd. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Pyxis Oncology presently has a consensus rating of “Moderate Buy” and a consensus target price of $7.20.

About Pyxis Oncology

Pyxis Oncology (NASDAQ: PYXS) is a clinical‐stage biotechnology company focused on the discovery and development of targeted oncology therapies. The company’s platform centers on antibody‐drug conjugates (ADCs) that deliver potent mitotic inhibitors directly to cancer cells, leveraging novel payloads designed to disrupt cell division. By combining highly specific antibodies with innovative cytotoxic agents, Pyxis Oncology aims to improve therapeutic windows and reduce off‐target toxicities common to conventional chemotherapies.

Since its inception, Pyxis Oncology has built a pipeline of early‐stage ADC candidates directed against a variety of solid tumor antigens.